title: Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine.
abstract: Toxoplasmosis can lead to severe pathology in both humans and animals. However, an effective vaccine for humans has not been successfully developed. In this study, we used multi-antigenic SAG1-ROP2 as a DNA vaccine and cholera toxin A2/B subunit and murine interleukin-12 to compare their effectiveness as genetic adjuvants. Bagg albino/c (BAL/c) mice were immunized intramuscularly with pcDNA3.1-SAG1-ROP2 alone (control group), or pcDNA3.1-SAG1-ROP2 with co-administration of pCTA2/B or pIL-12, respectively. After immunization, the effectiveness of these two adjuvants were compared using lymphocyte proliferation assay, cytokine and antibody measurements. The group co-administered pIL-12 elicited stronger humoral and Th1-type cellular immune responses than those immunized with pcDNA3.1-SAG1-ROP2 alone, while in the group co-administered pCTA2/B there was no obvious enhancement of immunity. When challenged with Toxoplasma gondii RH strain, mice immunized with pIL-12 co-administration had significantly higher survival rates, whereas there was no notable augmentation of immunity in pCTA2/B group. Therefore, since pIL-12 significantly enhanced the antigenicity of multi-antigenic DNA vaccine, this suggests that IL-12 is a better and more effective adjuvant than CTA2/B in this situation.
authors.affiliation: Department of Parasitology, School of Medicine, Shandong University, No. 44 Wenhuaxi Road, Jinan, Shandong 250012, PR China.
authors.forename: Mingfu
authors.initials: M
authors.lastname: Xue
authors.forename: Shenyi
authors.initials: S
authors.lastname: He
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Yuling
authors.initials: Y
authors.lastname: Cui
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yao
authors.forename: Huaxin
authors.initials: H
authors.lastname: Wang
mesh_terms: D000276:Adjuvants, Immunologic / Q000592:standards*; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology; D002772:Cholera Toxin / Q000276:immunology / Q000592:standards*; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D018664:Interleukin-12 / Q000276:immunology / Q000592:standards*; D008213:Lymphocyte Activation; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology; D051379:Mice; D010957:Plasmids / Q000276:immunology; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology; D016052:Protozoan Vaccines; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000166:cytology / Q000276:immunology; D015996:Survival Rate; D014122:Toxoplasma / Q000235:genetics / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000401:mortality / Q000517:prevention & control; D019444:Vaccines, DNA
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; D007074:Immunoglobulin G; D008565:Membrane Proteins; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; C090555:ROP 2 protein, Toxoplasma gondii; C047168:SAG1 antigen, Toxoplasma; D019444:Vaccines, DNA; D018664:Interleukin-12; D002772:Cholera Toxin